A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

94 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-30

Study Completion Date

2023-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to explore the levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, in patients with hepatocellular carcinoma (HCC). The goal is to determine whether AFP levels vary based on the size of the liver tumor or other health conditions like hepatitis B, hepatitis C, and obesity. By analyzing data from 94 patients, the study seeks to identify factors that influence AFP levels, which may help in understanding liver cancer progression and improving diagnosis and treatment approaches.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study

NCT00629421

Cirrhosis Hepatocellular Carcinoma

COMPLETED

Role of Early API in Accurately Differentiating Hepatocellular Carcinoma From Dysplastic Nodules in Cirrhotic Patients

NCT07080372

Dysplastic Nodule

ACTIVE_NOT_RECRUITING

Hepatocellular Cancer (HCC) Screening in Zhongshan City

NCT02501980

Liver Neoplasms

UNKNOWN

Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City

NCT07010198

Hepatocellular Cancer (HCC)

RECRUITING

Evaluation of Proteome Multimarker Panel With Multiple Reaction Monitoring as a Surveillance for Hepatocellular Carcinoma

NCT05756699

Liver Cirrhosis

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Hepatocellular

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: HCC Patients with Elevated AFP Levels Description: This group includes patients diagnosed

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 27 to 80 years.
* Diagnosed with hepatocellular carcinoma (HCC) within the last three months.
* Diagnosis confirmed by relevant investigations (e.g., imaging, liver biopsy).
* Able to provide informed consent.

Exclusion Criteria

* Elevated alpha-fetoprotein levels due to tumors other than HCC.
* Presence of secondary liver metastases from other primary sites.
* Any significant comorbid conditions that could interfere with study assessments.
* Pregnancy or breastfeeding.

Minimum Eligible Age

27 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No